Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade

The association between tumor mutational burden and prognosis is dependent on treatment context

(2021) Cristina Valero et al.   NATURE GENETICS

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

(2021) Kevin Litchfield et al.   CELL

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

(2021) Cristina Valero et al.   Nature Communications

Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors

(2021) Jose Mauricio Mota et al.   JOURNAL OF IMMUNOTHERAPY

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

(2021) Chung-Han Lee et al.   MOLECULAR CANCER RESEARCH

Using DNA sequencing data to quantify T cell fraction and therapy response

(2021) Robert Bentham et al.   NATURE

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

(2021) Thomas Powles et al.   NATURE

Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management

(2021) Mamta Parikh et al.   American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project

(2020) Diana M Merino et al.   Journal for ImmunoTherapy of Cancer

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

(2020) V. Subbiah et al.   ANNALS OF ONCOLOGY

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

(2020) Sangeeta Goswami et al.   Science Translational Medicine

Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer

(2020) Zhe Gong et al.   Cancer Medicine

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors

(2020) Marcin Nicoś et al.   Frontiers in Oncology

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

(2019) Y Fradet et al.   ANNALS OF ONCOLOGY

TMB standardization by alignment to reference standards: Phase II of the Friends of Cancer Research TMB Harmonization Project.

(2019) Diana M. Merino et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across metastatic cancer

(2019) Li Liu et al.   CLINICAL CANCER RESEARCH

Lack of detectable neoantigen depletion signals in the untreated cancer genome

(2019) Jimmy Van den Eynden et al.   NATURE GENETICS

Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy

(2019) Diego Chowell et al.   NATURE MEDICINE

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

(2019) Thomas Powles et al.   NATURE MEDICINE

Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma

(2019) Janis V. de la Iglesia et al.   CLINICAL CANCER RESEARCH

Identification of an immunotherapy-responsive molecular subtype of bladder cancer

(2019) Bic-Na Song et al.   EBioMedicine

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

(2018) Thomas Powles et al.   LANCET

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

(2017) Andrea B. Apolo et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

(2017) Padmanee Sharma et al.   LANCET ONCOLOGY

Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy

(2017) Kenneth M. Felsenstein et al.   Nature Reviews Urology

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

(2017) Diego Chowell et al.   SCIENCE

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

(2017) Thomas Powles et al.   JAMA Oncology

Toward a Shared Vision for Cancer Genomic Data

(2016) Robert L. Grossman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Systematic pan-cancer analysis of tumour purity

(2015) Dvir Aran et al.   Nature Communications

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution

(2014) Christopher A. Miller et al.   PLoS Computational Biology

Inferring tumour purity and stromal and immune cell admixture from expression data

(2013) Kosuke Yoshihara et al.   Nature Communications

MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma

(2012) Edmund A. Mroz et al.   ORAL ONCOLOGY